These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 25757613)

  • 21. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
    Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of hepatitis C: current status and perspectives].
    Pol S; Corouge M
    Rev Prat; 2014 May; 64(5):605-12. PubMed ID: 24923038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
    Matthews SJ; Lancaster JW
    Clin Ther; 2012 Sep; 34(9):1857-82. PubMed ID: 22951253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
    J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
    Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Progress in Examination and Treatment of Hepatitis C Virus].
    Suda G; Sakamoto N
    Rinsho Byori; 2015 Jun; 63(6):762-7. PubMed ID: 26548242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New therapeutic opportunities for hepatitis C based on small RNA.
    Pan QW; Henry SD; Scholte BJ; Tilanus HW; Janssen HL; van der Laan LJ
    World J Gastroenterol; 2007 Sep; 13(33):4431-6. PubMed ID: 17724797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Research advances on treatment of hepatitis C infection based on RNA interference and microRNA modulation].
    Liu YN; Lou GH; Chen Z
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2011 Nov; 40(6):609-16. PubMed ID: 22190521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current and evolving therapies for hepatitis C.
    Moradpour D; Blum HE
    Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1199-202. PubMed ID: 10563526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Animal model for hepatitis C virus infection].
    Tsukiyama-Kohara K; Kohara M
    Uirusu; 2015; 65(2):255-262. PubMed ID: 27760924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. microRNAs: novel players in hepatitis C virus infection.
    Li X; Yang W; Ye W; Jin L; He J; Lou L
    Clin Res Hepatol Gastroenterol; 2014 Dec; 38(6):664-75. PubMed ID: 24875730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospects for nucleic acid-based therapeutics against hepatitis C virus.
    Lee CH; Kim JH; Lee SW
    World J Gastroenterol; 2013 Dec; 19(47):8949-62. PubMed ID: 24379620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of hepatitis C virus replication using adeno-associated virus vector delivery of an exogenous anti-hepatitis C virus microRNA cluster.
    Yang X; Haurigot V; Zhou S; Luo G; Couto LB
    Hepatology; 2010 Dec; 52(6):1877-87. PubMed ID: 20931557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic potential of RNA interference: a new molecular approach to antiviral treatment for hepatitis C.
    Motavaf M; Safari S; Alavian SM
    J Viral Hepat; 2012 Nov; 19(11):757-65. PubMed ID: 23043382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic strategies and promising vaccine for hepatitis C virus infection.
    Adugna A
    Immun Inflamm Dis; 2023 Aug; 11(8):e977. PubMed ID: 37647422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional foods effective for hepatitis C: Identification of oligomeric proanthocyanidin and its action mechanism.
    Ishida Y; Takeshita M; Kataoka H
    World J Hepatol; 2014 Dec; 6(12):870-9. PubMed ID: 25544874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Future promise of siRNA and other nucleic acid based therapeutics for the treatment of chronic HCV.
    Wilson JA; Richardson CD
    Infect Disord Drug Targets; 2006 Mar; 6(1):43-56. PubMed ID: 16787303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular therapies for viral hepatitis.
    Guha C; Shah SJ; Ghosh SS; Lee SW; Roy-Chowdhury N; Roy-Chowdhury J
    BioDrugs; 2003; 17(2):81-91. PubMed ID: 12641487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C variability, patterns of resistance, and impact on therapy.
    Strahotin CS; Babich M
    Adv Virol; 2012; 2012():267483. PubMed ID: 22851970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C virus infection--pathobiology and implications for new therapeutic options.
    Davis GL; Krawczynski K; Szabo G
    Dig Dis Sci; 2007 Apr; 52(4):857-75. PubMed ID: 17333350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.